News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
684,318 Results
Type
Article (39003)
Company Profile (277)
Press Release (645038)
Section
Business (203845)
Career Advice (1987)
Deals (35359)
Drug Delivery (85)
Drug Development (80779)
Employer Resources (168)
FDA (16085)
Job Trends (14801)
News (344499)
Policy (32431)
Tag
Academia (2530)
Alliances (49053)
Alzheimer's disease (1219)
Approvals (16007)
Artificial intelligence (124)
Bankruptcy (352)
Best Places to Work (11505)
Biotechnology (196)
Breast cancer (114)
Cancer (995)
Cardiovascular disease (83)
Career advice (1657)
Cell therapy (213)
Clinical research (64045)
Collaboration (346)
Compensation (183)
COVID-19 (2523)
C-suite (86)
Data (977)
Diabetes (145)
Diagnostics (6116)
Earnings (84534)
Employer resources (146)
Events (109197)
Executive appointments (267)
FDA (16558)
Funding (309)
Gene therapy (159)
GLP-1 (569)
Government (4321)
Healthcare (18659)
Infectious disease (2604)
Inflammatory bowel disease (103)
Interviews (308)
IPO (16279)
Job creations (3623)
Job search strategy (1415)
Layoffs (410)
Legal (7851)
Lung cancer (159)
Manufacturing (160)
Medical device (13158)
Medtech (13163)
Mergers & acquisitions (19125)
Metabolic disorders (381)
Neuroscience (1470)
NextGen Class of 2024 (6497)
Non-profit (4463)
Northern California (1336)
Obesity (223)
Opinion (177)
Patents (96)
People (56173)
Phase I (19887)
Phase II (28203)
Phase III (21044)
Pipeline (328)
Postmarket research (2553)
Preclinical (8455)
Radiopharmaceuticals (234)
Rare diseases (196)
Real estate (5888)
Regulatory (21468)
Research institute (2307)
Resumes & cover letters (349)
Southern California (1186)
Startups (3560)
United States (12481)
Vaccines (544)
Weight loss (164)
Date
Today (131)
Last 7 days (958)
Last 30 days (3329)
Last 365 days (35347)
2024 (31425)
2023 (40074)
2022 (51173)
2021 (55712)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (188)
Asia (37061)
Australia (6043)
California (3004)
Canada (1216)
China (234)
Colorado (130)
Connecticut (137)
Europe (79345)
Florida (418)
Georgia (107)
Illinois (328)
Indiana (188)
Kansas (96)
Maryland (549)
Massachusetts (2413)
Michigan (149)
Minnesota (260)
New Jersey (884)
New York (891)
North Carolina (676)
Northern California (1336)
Ohio (129)
Pennsylvania (790)
South America (1091)
Southern California (1186)
Texas (414)
Utah (84)
Washington State (338)
684,318 Results for "avirmax inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Avirmax Inc. to Present at the ARVO Frontiers in Ocular Gene Therapy Research Conference
November 12, 2024
·
2 min read
Biotech Bay
Avirmax Inc. to Make Scientific Presentations at ASGCT in Baltimore
Avirmax Inc., will make two scientific presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) annual meeting in Baltimore between May 7th and 11th, 2024.
April 16, 2024
·
2 min read
Drug Development
Avirmax Biopharma Inc. Receives IND Approval for Phase I/IIa Trial to Treat Wet AMD including PCV
Avirmax Biopharma, Inc. is pleased to announce that it has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase I/IIa clinical trial for its gene therapy treatment targeting wet Age-related Macular Degeneration.
May 30, 2024
·
2 min read
Biotech Bay
Avirmax Biopharma Inc. to Present at the 2024 ARVO Annual Meeting in Seattle
Avirmax Biopharma Inc., will make three scientific presentations at the 2024 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Seattle between May 5th and 9th, 2024.
April 1, 2024
·
2 min read
Press Releases
Avirmax Biopharma Inc. to Exhibit Development of Next Generation Gene Therapies for Ocular Diseases at the AAO 2024 Annual Meeting in Chicago
October 15, 2024
·
2 min read
Biotech Bay
Avirmax Inc. Will Attend the BioProcess International Meeting in Boston
Avirmax Inc., Vice President of Research, Dr. Li Ou, and Associate Director of Operations, Ms. June Song , will attend the BioProcess International meeting in Boston between September 18th to 21st , 2023.
September 13, 2023
·
2 min read
Biotech Bay
Avirmax Biopharma Inc. Will Present at Glaucoma 360 New Horizons Forum 2023
Avirmax Biopharma Inc. (ABI), Chief Executive and Scientific Officer, Shengjiang Shawn Liu will present the Avirmax BioPharma Inc (ABI)'s progress in the innovation and development of genetic medicines for glaucoma treatment at Glaucoma 360 New Horizons Forum at The Westin St. Francis in San Francisco, Feb 03, 2023.
February 3, 2023
·
2 min read
Biotech Bay
Avirmax Biopharma Inc. Will Present at the 26th ASGCT 2023 Annual Conference in Los Angeles
Avirmax Biopharma Inc. (ABI), Chief Executive and Scientific Officer, Shengjiang Shawn Liu will present results of a three-year study that systematically compared the recombinant adeno-associated virus (rAAV) vector products manufactured using insect Sf9 and human HEK293 cell culture systems at the 26th ASGCT annual conference in Los Angeles, at 2:30 pm. of May 18.
May 17, 2023
·
2 min read
Biotech Bay
Avirmax CMC Inc. Successfully Manufactured and Delivered to a Client the First Lot of rAAV Drug Product for a Monkey Toxicology Study
Avirmax CMC Inc. (ACI), a global leader in recombinant adeno associated vector (rAAV) bioprocess development and manufacturing, using a recombinant baculovirus Sf9 cell (rBV-Sf9-AAV) system, has manufactured, tested and released its first batch of rAAV product for use in monkey toxicology and pharmacology studies for an ocular indication.
December 15, 2022
·
2 min read
Biotech Bay
Avirmax Inc. Announces Issuance of U.S. Patent Covering Catalysis Deactivated Angiotensin-Converting Enzyme 2 (ACE2) Variants for Treatment of Beta Group SARS-COV Viral Infection
Avirmax Inc.(www.avirmax.com) announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,453,869, which is directed to the composition and methods related to the use and administration of catalysis deactivated angiotensin-converting enzyme 2 (ACE2) for preventing SARS-COV-1 and SARS-COV-2 infection.
October 7, 2022
·
2 min read
1 of 68,432
Next